Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · IRADIMED CORP (IRMD)

Iradimed Q2 revenue up 0.5% to $20.5 million; EPS falls to $0.41; guidance reaffirmed

Mixed Impact 3 of 5 earnings Written later

IRADIMED reported second-quarter 2026 revenue of $20.5 million, up 0.5% from a year earlier, while net income fell 10% to $5.2 million and diluted EPS fell to $0.41 from $0.45. The company reaffirmed its full-year 2026 revenue and EPS guidance and declared a $0.20 per share quarterly dividend. Management said the first production ramp of the new 3870 IV pump met its plan, and the quarterly gross profit margin fell to 74% from 78%.

Key points

  • Q2 2026 revenue was $20.5 million, up $0.1 million from $20.4 million in Q2 2025.
  • Q2 2026 GAAP diluted EPS was $0.41 versus $0.45 a year earlier; non-GAAP diluted EPS was $0.46 versus $0.49.
  • Full-year 2026 guidance reaffirmed: revenue of $91.0 million to $96.0 million and GAAP diluted EPS of $1.90 to $2.05.
  • Q3 2026 guidance: revenue of $23.0 million to $24.5 million and GAAP diluted EPS of $0.49 to $0.54.

The filing

CompanyIRADIMED CORP (IRMD)
Form8-K, current report
Filed with the SECJul 31, 2026, 8:15 AM ET
Accession number0001628280-26-051240

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 31, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.